This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 3, 2011 /PRNewswire/ --
Vista Partners announced today that it has initiated coverage on
Cellmid Ltd. (ASX: CDY) (the "Company") with a twelve month target price of AUD
Ross Silver, Principal Analyst at Vista Partners stated, "We believe Cellmid represents a significant value proposition to a potential collaborator considering the breadth of the Company's midkine ("MK") patents. The size of the market its therapeutics could compete, if approved, is in excess of
$15 billion." Mr. Silver continued, "Cellmid has a large portfolio of patents surrounding MK and owns 21 patent families worldwide. Cellmid plans to monetize this portfolio through two segments: Diagnostics and Therapeutics. The diagnostic programs are in a more advanced stage and are poised to face regulatory approvals first. The therapeutic programs are in pre-clinical trials; however they involve high value antibody candidates with early partner/licensing potential." Mr. Silver concluded, "Cellmid is the second Australian biotechnology company we have covered, the previous Australian biotech company we covered was named Arana and they were acquired by
Cephalon (ticker: CEPH) for
$318M in 2009."
To download a FREE copy of the
Cellmid Ltd. research report, please visit
www.vistapglobal.com and complete the research form to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of
Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of
profitable investment ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website
www.vistapglobal.com or click
SOURCE Vista Partners